Halozyme Therapeutics (HALO) shares outstanding
Halozyme Therapeutics (HALO) had 123.90M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 4.3% lower than the 129.42M of fiscal 2024. Figures as of 18 Nov 2026, 12:33 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Shares outstanding, fiscal 2025
- 123.90M
- Change on fiscal 2024
- −4.3%
- Growth, 5 years
- −2.6% a year
- Growth, 10 years
- −0.2% a year
- Highest on record
- 146.80Mfiscal 2021
- Lowest on record
- 123.90Mfiscal 2025
- Fiscal years on record
- 112015–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Halozyme Therapeutics shares outstanding, in more detail
The market data feed counts 114.01M shares outstanding today.
Over the five fiscal years to 2025 the diluted share count shrank at a compound 2.6% a year; over ten years the rate was −0.2% a year. Across the 11 fiscal years on record (2015–2025), the highest was 146.80M in fiscal 2021 and the lowest 123.90M in fiscal 2025.
Shares outstanding by fiscal year
Halozyme Therapeutics shares outstanding, year by year
| Fiscal year | Shares outstanding | Change | Year ended |
|---|---|---|---|
| 2025 | 123.90M | 4.3% down | |
| 2024 | 129.42M | 3.6% down | |
| 2023 | 134.20M | 4.6% down | |
| 2022 | 140.61M | 4.2% down | |
| 2021 | 146.80M | 3.8% up | |
| 2020 | 141.46M | 2.0% down | |
| 2019 | 144.33M | 0.5% up | |
| 2018 | 143.60M | 3.3% up | |
| 2017 | 139.07M | 8.7% up | |
| 2016 | 127.96M | 1.0% up | |
| 2015 | 126.70M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.
How to read it
A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.
Shares outstanding at health care companies of similar size
| Company | Shares outstanding | Fiscal year |
|---|---|---|
| Fresenius Medical Care FMS | 582.38M | 2025 |
| Kymera Therapeutics KYMR | 84.49M | 2025 |
| DaVita DVA | 75.89M | 2025 |
| Halozyme Therapeutics HALO | 123.90M | 2025 |
| Universal Health Services UHS | 64.46M | 2025 |
| Repligen RGEN | 56.56M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Halozyme Therapeutics, figure by figure
- Halozyme Therapeutics market cap
- Halozyme Therapeutics revenue
- Halozyme Therapeutics earnings
- Halozyme Therapeutics earnings per share (EPS)
- Halozyme Therapeutics P/E ratio
- Halozyme Therapeutics P/S ratio
- Halozyme Therapeutics P/B ratio
- Halozyme Therapeutics free cash flow
- Halozyme Therapeutics operating margin
- Halozyme Therapeutics dividend
- Halozyme Therapeutics total debt
- Halozyme Therapeutics cash on hand
- Halozyme Therapeutics total assets
- Halozyme Therapeutics return on equity (ROE)
- Halozyme Therapeutics return on invested capital (ROIC)
Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value
Halozyme Therapeutics shares outstanding: questions and answers
How many shares does Halozyme Therapeutics have?
Halozyme Therapeutics (HALO) had 123.90M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 4.3% lower than the 129.42M of fiscal 2024. The market data feed counts 114.01M shares outstanding today.
What is the growth rate of Halozyme Therapeutics's diluted share count?
Over the five fiscal years to 2025 the diluted share count shrank at a compound 2.6% a year; over ten years the rate was −0.2% a year.
What are the highest and lowest diluted share count figures on record for Halozyme Therapeutics?
Across the 11 fiscal years on record (2015–2025), the highest was 146.80M in fiscal 2021 and the lowest 123.90M in fiscal 2025.
How is Halozyme Therapeutics's diluted share count calculated?
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For Halozyme Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: shares outstanding
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Halozyme Therapeutics (HALO) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/shares-outstanding
Underlying data: the company's filings with the SEC and Yahoo Finance.